The biological rationale and clinical efficacy of inhibition of signaling kinases in chronic lymphocytic leukemia

Research output: Contribution to journalReview articleAcademicpeer-review

5 Citations (Scopus)


Chronic lymphocytic leukemia (CLL) is still incurable, with considerable resistance to the standard therapy. CLL cells receive anti-apoptotic and pro-proliferation stimuli in lymph nodes and bone marrow, mainly through B cell receptor activation and TNF-receptor family ligation. In recent years, the focus for finding new drugs has shifted to blocking signals from the microenvironment. Novel therapeutical agents interfere with these microenvironmental interactions, and include inhibitors of kinases Syk, Btk and PI3Kδ. In this review we will focus on the microenvironmental interactions of CLL and the role of tyrosine kinases. Furthermore, early results from clinical trials with kinase inhibitors are discussed
Original languageEnglish
Pages (from-to)838-847
JournalLeukemia research
Issue number7
Publication statusPublished - 2013

Cite this